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Background: Radiotherapy is an established treatment for malignant localised disease. Pan-
creatic cancer however seems relatively insensitive to this form of therapy.
Methods: Pancreatic cancer cell lines MiaPaca-2 and Panc-1 were pre-treated with 3000 IU/
ml IFNa or 100 IU/ml IFNb followed by 0, 2, 4, or 6 Gray (Gy) irradiation. Colony forming
assay was used to assess the effects on cellgrowth. To measure the surviving fraction at
the clinically relevant dose of 2 Gy (SF2), cells were pre-treated with 1000–10.000 IU/ml IFNa
or 50–500 IU/ml IFNb followed by 2 Gy irradiation.
Results: The plating efficiency was 49% for MiaPaca-2 and 22% for Panc-1. MiaPaca-2 was
more radiosensitive than Panc-1 (surviving fraction of 0.28 versus 0.50 at 4 Gray). The SF2
of MiaPaca-2 was 0.77 while the SF2 of Panc-1 was 0.70. The SF2 significantly decreased
after pretreatment with IFNa 1000 IU/ml (p < 0.001) and IFNb 100 IU/ml (p < 0.001) in Mia-
Paca-2 and with IFNa 5000 IU/ml (p < 0.001) and IFNb 100 IU/ml (p < 0.01) in Panc-1. The sen-
sitising enhancement ratio (SER) for IFNa 3000 IU/ml was 2.15 in MiaPaca-2 and 1.90 in
Panc-1. For IFNb 100 IU/ml the SER was 1.72 for in MiaPaca-2 and 1.51 in Panc-1.
Conclusions: Type I interferons have radiosensitising effects in pancreatic cancer cell lines.
This radiosensitising property might lead to an improved response to treatment in pancre-
atic cancer. Interferon b is the most promising drug due to its effect in clinically obtainable
doses.
 2011 Elsevier Ltd. Open access under the Elsevier OA license.1. Introduction
Radiotherapy is an important treatment in cancer, especially
for patients with advanced localised disease, with proven effi-
cacy in many tumours.1–5 Based on several randomised
controlled trials studying the effect of adjuvant (chemo)radio-
therapy, pancreatic and periampullary cancers are fairly
radiotherapy resistant.6–10t of Surgery, Erasmus Me
31 10 7033350.
l (C.H.J. van Eijck).
the Elsevier OA license.Often chemotherapeutics (5-fluorouracil (5-FU), gemcita-
bine) are used as radiosensitisers. Besides their direct cyto-
toxic effects caused by incorporation of the drugs as
modified nucleotides into the DNA, even low doses of these
drugs can be effective in radiosensitisation. Interference with
normal repair of radiation-induced DNA damage with an inap-
propriate progression through S phase is key in their radiosen-
sitising properties causing late, unmanageable toxicities. Adical Centre Rotterdam’s, Gravendijkwal 230, 3015 CE Rotterdam,
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increase in oxygenation, leading to an increased vulnerability
for radiotherapy.11,12 However, as mentioned, results of che-
moradiotherapy are disappointing in pancreatic cancer.6–10
In several tumours radiosensitising properties of inter-
feron alpha (IFNa) and interferon beta (IFNb) have been dem-
onstrated in vitro13–17 as well as in vivo.18,19 In pancreatic
cancer cell lines, IFNa has already shown to act as radiosensi-
tiser20 and in vivo promising therapy results have been re-
ported combining 5-FU, cisplatinum, and radiation therapy
with IFNa alone (5-year survival rate of 55%) or followed by
2 cycles of gemcitabine (median survival 25 months) in pa-
tients with resected pancreatic adenocarcinoma.21,22 These
results are currently reinvestigated in the phase III CapRI
study.23
Type I interferons such as IFNa and IFNb, sort their effect
through the same interferon receptor (IFNAR) with IFNb hav-
ing a higher affinity. In vivo studies showed that approximately
20% of pancreatic cancers express IFNARs and that expression
of the interferon receptor correlates with a significant survival
benefit in patients with resected pancreatic cancer.24
The exact mechanism by which type I interferons cause
radiosensitisation is unclear. Possibly, concomitant treatment
with IFNs causes an inappropriate progression of cells into
S-phase, thereby interfering with repair of radiation-induced
damage or increasing the proportion of lethal to sublethal
damage.17,25
In this study we aim to gain insight in the radiosensitising
abilities of type I interferons, especially IFNb, in pancreatic
cell lines. We decided to address these issues in colony form-
ing assays, because besides the apoptotic effects of radiation
and IFNs, the reproductive integrity of tumour cells (i.e. the
capacity to produce an expanding colony of descendants,
and therefore to regrow the tumour if left intact at the end
of treatment) is of pivotal importance.
2. Materials and methods
2.1. Cell lines and culture conditions
The human pancreatic cell lines MiaPaCa-2 and Panc-1 were
purchased from the American Type Culture Collection. The
cells were cultured in a humidified incubator containing 5%
CO2 at 37C. MiaPaca-2 was cultured in RPMI 1640 and Panc-
1 in DMEM both supplemented with 10% FCS, penicillin
(1 · 105 U/l), fungizone (0.5 mg/l) and L-glutamine (2 mmol/l).
Periodically, the cells were tested for Mycoplasma contamina-
tion, which was not detected. Cells were harvested with tryp-
sin (0.05%), EDTA (0.02%) and resuspended in medium. Before
plating, the cells were counted microscopically using a stan-
dard haemocytometer. Tryphan Blue staining was used to as-
sess cell viability, which always exceeded 95%. Media and
supplements were obtained from GIBCO Bio-cult Europe
(Invitrogen, Breda, The Netherlands).
2.2. Drugs and Reagents
Human recombinant IFN-a-2b (Intron-A) was obtained from
Schering-Plough Corporation (Utrecht, The Netherlands),
while human recombinant IFN-b-1a (Rebif) was acquired fromSerono Benelux BV (Den Haag, The Netherlands). All com-
pounds were stored at )20 C, and the stock solution was con-
stituted in distilled water according to the manufacturer
instructions. Doses of 1000–10.000 IU/ml for IFNa and
50–500 IU/ml for IFNb were used.
2.3. Irradiation
Cells were exposed to gamma radiation from a 137Cs source at
70.9 cGy/min at room temperature under aerobic conditions.
For radiation survival studies, cells were irradiated with 0, 2,
4, 6, 8, or 10 Gray. In the combined modality treatment, the
IFN treatment was given before irradiation for 72 hours. Cells
were irradiated with 0, 2, 4, or 6 Gray in the presence of the
drug.
2.4. Colony forming assay
Cells were plated onto poly-L-lysine coated, 60-mm Petri-
dishes (6–12 cells/cm2) and cultured in complete medium for
2 weeks. Poly-L-lysine (10 lg/ml; Sigma–Aldrich, Zwijndrecht,
The Netherlands) inhibited cells from dispersing from the
growing colonies.
Dose response curves for IFNa, IFNb and irradiation were
established for both cell lines using a colony-forming assay.
Therefore, seeded cells were allowed to attach for 24 hour
prior to treatment with 1000–10.000 IU/ml IFNa, 50–500 IU/
ml IFNb or 0–10 Gray irradiation. Cell lines were treated with
IFNs continuously and medium plus agents were replaced
every three or four days. Fourteen days after seeding, colonies
were fixed with 100% ethanol and stained with hematoxicil-
line to allow calculation of their average colony-forming effi-
ciency. Colonies containing >50 cells were counted
automatically with the MultiImage Light Cabinet from HpH
Innitech Corporation.
Plating efficiency was defined as the mean number of col-
onies divided by the number of inoculated cells for control
cultures not exposed to interferons or radiation. The surviv-
ing fraction (SF) was calculated as (mean number of colo-
nies)/(number of inoculated cells · plating efficiency). The
curve was plotted using X–Y log scatter (Graph Prism 3.0).
Curve-fitting parameters a and b were determined.2.5. Radiation enhancement by type I interferons
To asses radiation enhancement by type I interferons, cells
were pretreated with IFNa 3000 IU/ml or IFNb 100 IU/ml (doses
resulting in approximately 50% decrease in surviving fraction
in both cell lines) for 72 hours. Cell lines were irradiated with
0, 2, 4, or 6 Gray. Control plates without IFNs were irradiated
simultaneously. Cell lines were treated with IFNs continu-
ously and medium plus agents were replaced every three or
four days. After 2 weeks, the formed colonies were fixed and
stained to allow counting.
SF2 is the surviving fraction of cells that were irradiated at
the clinically relevant dose of 2 Gray.
The sensitising enhancement ratio (SER) for interferon
was calculated at the 37% survival level. The radiation dose
that reduced the surviving colonies to 37% of the non-treated
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vival to 37% after interferon pre-treatment.
2.6. Cell proliferation assay
Measurement of total DNA contents, representative for the
number of cells, was performed using the bisbenzimide fluo-
rescent dye (Hoechst 33258, Boehring Diagnostics, La Jolla,
CA) as previously described.26
2.7. Measurement of DNA fragmentation (apoptosis)
10.000 cells/dish, depending on the length of the incubation
period, were plated on 24-well plates and the cells were al-
lowed to adhere overnight. The next day the cell culture med-
ium was replaced with 1ml/well medium containing 3000 IU/
ml IFN-a or 100 IU/ml IFN-b. Each treatment was performed
in quadruplicate. After an additional incubation of 3 days,
apoptosis was assessed using a commercially available ELISA
kit (Cell Death Detection ELISAPlus, Roche Diagnostic GmbH,
Penzberg, Germany). The standard protocol supplied by the
manufacturer was used. Relative apoptosis was determined
by calculating the ratio of the average absorbance of the treat-
ment dishes to the average absorbance of the control dishes.
The data were corrected for the effect on cell number after
3 days of treatment. Intra- and inter-assay coefficients of var-
iation were 4.2% and 6.3%, respectively.Fig. 1 – Effect of IFNa and IFNb treatment on colony forming abili
were treated with IFNa (A,C) or IFNb (B,D) during fourteen days
automatically. Data are the mean ± SEM. *p < 0.05 versus contro2.8. Statistical analyses
All experiments were carried out in duplicates and gave com-
parable results. For statistical analysis GraphPad Prism 3.0
(GraphPad Software, San Diego, USA) was used. The compar-
ative statistical evaluation amongst groups was firstly per-
formed by the ANOVA test. When significant differences
were found, a comparison between groups was made using
the Newman–Keuls test. The unpaired Student t-test was
used to analyse the differences in surviving fraction for each
dose point.
In all analyses, values of p < 0.05 were considered statisti-
cally significant. Data are reported as mean ± SEM. Statistical
analysis was made after logarithmic transformation.3. Results
In vitro, the control plating efficiency (mean ± SD) was mea-
sured and amounted to 49 ± 3% for MiaPaca-2 and 22 ± 3%
for Panc-1.
3.1. Effect of type I interferons on relative clonogenic
survival
Both IFNa and IFNb inhibited colony formation for both Mia-
Paca-2 and Panc-1 cells in a dose dependent manner (Fig. 1).ty in MiaPaca-2 (A,B) and Panc-1 (C,D). Pancreatic cancer cells
and both number and size of colonies were counted
l.
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nerable to both IFNa and IFNb than Panc-1.
Besides inhibiting colony formation, type I interferon
had growth inhibitory effects on both cell lines; after inter-
feron treatment, colonies were significantly smaller than
colonies from untreated cells (Fig. 1). This finding is con-
sistent with Vitale’s manuscript27 demonstrating both
growth inhibitory as well as pro-apoptotic properties of
type I interferons with IFNb being the more potent pro-
apoptotic drug than IFNa, where apoptosis only occurs in
higher doses.
3.2. Effect of radiation on relative clonogenic survival
MiaPaca-2 was more radiosensitive than Panc-1 for 4, 6 and
8 Gray (Fig. 2a). The surviving fraction at 2 Gy (SF2) of Mia-
Paca-2 was 0.77 while the SF2 of Panc-1 was 0.70. At 4 Gy how-
ever, the SF was 0.28 for MiaPaca-2 and 0.50 for Panc-1. The
size of the colonies was not considerably influenced by radio-
therapy (Fig. 2b).
3.3. Effect of type I Interferons on apoptosis
Significant apoptosis corrected for DNA content occurred
after 72 hours (Fig. 3). Apoptosis increased to 802 ± 219% for
IFNa 3000 IU/ml and 575 ± 119% for IFNb 100 IU/ml. In Panc-
1 apoptosis after 72 hours was 154 ± 14% for IFNa 3000 IU/ml
and 139 ± 7% for IFNb 100 IU/ml.Fig. 2 – Effect of irradiation on colony forming ability in MiaPac
irradiation during 14 days and both number and size of colonie
*p < 0.05 versus control.3.4. Surviving fraction at 2 Gray (SF2)
The SF2 of MiaPaca-2 was 0.77 while the SF2 of Panc-1 was
0.70.
Pre-incubation with IFNa for 72 hours at doses of 1000,
2000 or 5000 IU/ml changed the SF2 in MiaPaca-2 to 0.56,
0.47 and 0.18, respectively. In Panc-1 pre-incubation with IFNa
at doses of 2000, 5000, or 10.000 IU/ml changed the SF2 to 0.66,
0.22 and 0.18, respectively.
Pre-incubation with IFNb for 72 hours at doses of 50, 100,
or 200 IU/ml changed the SF2 in MiaPaca-2 to 0.70, 0.33 and
0.22, respectively. In Panc-1 pre-incubation with IFNb at doses
of 100, 200 or 500 IU/ml changed the SF2 to 0.48, 0.24 and 0.23,
respectively.
The decrease of SF2 compared to the SF2 without pre-incu-
bation was significant after IFNa 2000 IU/ml (p < 0.01) and
IFNa 5000 IU/ml (p < 0.001) and IFNb 100 IU/ml and IFNb
200 IU/ml (p < 0.001) in MiaPaca-2. In Panc-1 concentrations
of IFNaa 2000 IU/ml (p < 0.01), IFNa 5000 IU/ml (p < 0.001) and
IFNa 10.000 IU/ml (p < 0.001) and IFNb 100 IU/ml (p < 0.001)
IFNb 200 IU/ml (p < 0.001) IFNb 500 IU/ml (p < 0.001) resulted
in significant improved radiosensitivity (Fig. 4).
3.5. Effect of type I interferon on radiosensitivity
The radiotherapy dose required to reduce the surviving frac-
tion to 37% was 3.98 Gy in MiaPaca-2 for the non-treated con-
trols. After IFNa 3000 IU/ml, the required dose was 1.85 Gya-2 and Panc-1. Pancreatic cancer cells were treated with
s were counted automatically. Data are the mean ± SEM.
Fig. 3 – Effect of 3000 IU/ml IFNa and 100 IU/ml IFNb treatment on apoptosis (DNA fragmentation) in MiaPaCa-2 and Panc-1 cell
lines. Cells were incubated for 3 days without (control) or with the drugs indicated. Values are absorbance units and are
expressed as percent of the control. Data are the mean ± SEM. *p < 0.05 versus control.
Fig. 4 – Effect of combined treatment with type I interferons and 2 Gy irradiation on colony forming ability in MiaPaCa-2 (A,B)
and Panc-1 (C,D) cell lines. Cells were pretreated with IFNa (A,C) or IFNb (B,D) for 72 hours followed by irradiation with 2 Gy.
The formed colonies were automatically counted after 2 weeks. Data are the mean ± SEM. *p < 0.05 versus control.
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leads to a sensitising enhancement ratio (SER) of 2.15 for IFNa
3000 IU/ml and a SER of 1.72 for IFNb 100 IU/ml in MiaPaca-2.
In Panc-1 the required radiotherapy dose to reduce the SF
to 37% was 4.65 Gy for the non-treated controls. After IFNa
3000 IU/ml, the required dose was 2.45 Gy and after IFNb
100 IU/ml, the required dose was 3.07 Gy. This leads to a sen-
sitising enhancement ratio (SER) of 1.90 for IFNa 3000 IU/ml
and a SER of 1.51 for IFNb 100 IU/ml in Panc-1.
The shape of the survival curves changed after treatment
resulting in an increased steepness of the survival curve with
an increase of the a-component after curve fitting (Fig. 5). For
MiaPaca-2 this increase was significant for both IFNa as IFNbcompared to the non-treated controls. In the Panc-1, we
found no significant difference between the a-component
after neither IFNa nor IFNb and the non-treated controls. In
this cell line, after comparison of the radiosensitivity between
groups using the Newman–Keuls test, only the SF after 6 Gy of
irradiation combined with IFNa or IFNb was significantly low-
er than after irradiation alone. All other SFs were similar after
treatment or no treatment.
4. Discussion
Our in vitro study shows a radiosensitising effect of type I
interferons on pancreatic cancer cell lines MiaPaca-2 and
Fig. 5 – Effect of combined treatment with 3000 IU/ml IFNa
and 100 IU/ml IFNb and irradiation on colony forming ability
in MiaPaCa-2 and Panc-1 cell lines. Cells were pretreated with
IFNaor IFNb for 72 hours followed by 0, 2, 4 or 6 Gy irradiation.
The formed colonies were automatically counted after
2 weeks. Data are the mean ± SEM. *p < 0.05 versus control.
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apy after treatment with IFNa 3000 IU/ml and 1.72 times more
sensitive after IFNb 100 IU/ml. The sensitivity to radiotherapy
of Panc-1 increased 1.90 times after treatment with IFNa
3000 IU/ml and 1.51 times after IFNb 100 IU/ml. Radiosensiti-
sation was dose dependently, with higher doses of interferons
resulting in a higher radiosensitivity, i.e. a lower surviving
fraction at 2 Gray (SF2). Both overall radiosensitivity and sen-
sitivity to interferon therapy was higher in MiaPaca-2 than in
Panc-1. Previously, IFN receptor expression (mRNA and pro-
tein) was shown by Vitale et al.27 with MiaPaCa-2 expressing
more plasma membrane located IFN receptors than Panc-1.
Furthermore, treatment with type I interferons results in
more apoptosis in MiaPaca-2 than in Panc-1, although only
extremely high doses (>1000 IU/ml) of IFNa cause apoptosis.27
Tumours are most vulnerable for radiotherapy in case of
adequate vascular supply (proper oxygenation) and appropri-
ate cell cycling.11,28 To enhance the effect of radiotherapy, ef-
fort has been made to find radiation sensitisers. Because
hypoxic cells are known to be up to three-fold more resistant
to radiotherapy than well-oxygenated cells,29 several strate-
gies have been investigated to find ways to sensitise hypoxic
cells to radiation. These strategies focus at reducing tumour
hypoxia by increasing the delivery of oxygen to the tumour,
administering oxygen mimetics and mimicking the effect of
oxygen in the radiochemical process or by selective destruc-
tion of hypoxic cells, for instance by tirapazimine.30,31 Trials
show that reducing hypoxia by any means, leads to a better
locoregional control and an improved survival, especially in
head and neck cancer and cervical cancer.30Resistance to apoptosis is the key factor for poor responses
to therapies in pancreatic cancer. Ionising radiation alone
causes a range of lesions in the DNA of target cells such as base
damage, single-strand and double-strand breaks. Double-
strand breaks are generally considered the lethal event but
can be repaired by DNA repair mechanisms. Inadequately
repaired DNA damage causes activation of the mitochondrial
pathway of apoptosis by p53 resulting in activation of the cas-
pase cascade. Membrane damage activates the stress-activated
protein kinase pathway leading to activation of the mitochon-
drial pathway as well as a direct activation of caspases. Further-
more radiotherapy activates apoptosis due to stimulation of the
death receptor pathway, consisting of the tumour necrosis
factor (TNF) receptor superfamily (for instance TRAIL-R1 and
TRAIL-R2). Activation causes direct activation of the caspase
cascade. These cell death pathways are regulated by numerous
signalling molecules, such as nuclear factor-jB (NF-jB), phos-
phatidylinositol 3-kinase (PI3K), inhibitor of apoptosis proteins
(IAPs) and members of the Bcl-2 protein family.32,33
Pancreatic cancer cells have developed multiple resistance
mechanisms to therapy-induced apoptosis. The mitochon-
drial pathway of apoptosis is less activated due to inactivating
p53 mutations, present in >70% of the pancreatic cancers. If
activated, this pathway has a diminished ability to activate
the caspase cascade. Furthermore, pancreatic cancer cells
overexpress anti-apoptotic proteins, have inactivated pro-
apoptotic genes and express decoy receptors to prevent
activation of the death receptor pathway.34,35
In pancreatic cancer cell lines, IFNahas already shown to be
able to avoid these resistance mechanisms and act as radio-
sensitiser20 The exact mechanism by which IFN exerts this
radiosensitising activity is unclear. Both IFNa and IFNbhave di-
rect anti-tumour effects including apoptosis, cell damage,
upregulation of cancer antigens and a growth inhibitory effect
with accumulation of cells in S phase. Indirect anti-tumour ef-
fects are caused by modulation of the immune system, mainly
through activation of T-cells, macrophages and natural killer
cells, and anti-angiogenesis activity by downregulation of
the vascular endothelial growth factor (VEGF) receptor and
an alteration in the expression of various oncogenes.27,36–39
In pancreatic cancer cell lines, type I interferons cause
both direct apoptosis (at lower doses in IFNb) and radiosensi-
tisation. The exact mechanism for enhancing radiosensitivity
is unclear. Apparently the accumulation of cells in S phase
caused by interferons, which is the most radioresistant part
of the cell cycle, does not prevent radiosensitisation. A possi-
ble mechanism is the inability of cells to accumulate suble-
thal DNA damage with interferon interfering in the repair of
this kind of DNA damage. Furthermore alteration in oncogene
expression levels might sensitise radioresistant cells to radio-
therapy. Because not only the pro-apoptotic effect of IFNs
combined with radiotherapy but especially the reproductive
capacity of the treated cells is related to treatment efficacy,
we chose colony forming assays for our study.
Beneficial effects of IFNa combined with chemoradiother-
apy were already demonstrated in phase II studies in patients
with resectable pancreatic cancer.21,22 However, treatment is
associated with considerable toxicity21,22,40 and the optimal
combination therapy considering efficacy as well as tolerabil-
ity is yet to be determined.
1944 E U R O P E A N J O U R N A L O F C A N C E R 4 7 ( 2 0 1 1 ) 1 9 3 8 –1 9 4 5In conclusion, our in vitro study shows that both IFNa and
IFNb have radiosensitising effects in pancreatic cancer cell
lines that are not based on immunomodulatory properties.
Radiosensitising effects are dose dependent, and lower doses
of IFNb than IFNa cause similar radiosensitisation. The effect
of interferon seems related to the receptor status. The
radiosensitising property of type I interferons might lead to
an improved response to treatment in pancreatic cancer with
interferon b being the most promising drug. Therefore, fur-
ther clinical trials involving combination therapy of type I
IFNs and radiotherapy are promising.
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